Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae

Clinical Microbiology and Infection

Volumn 22, Issue 2, 2016, Pages 147-153

  Oliva, A ^a   Gizzi, F ^a   Mascellino, M T ^a   Cipolla, A ^a   D'Abramo, A ^a   D'Agostino, C ^a   Trinchieri, V ^a   Russo, G ^a   Tierno, F ^a   Iannetta, M ^a   Mastroianni, C M ^a   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bactericidal activity; Carbapenem resistant Klebsiella pneumoniae; Double carbapenem regimen; Sepsis; Synergy; Time kill studies

Indexed keywords

COLISTIN; ERTAPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAM; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL ARTICLE; COLONY FORMING UNIT; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; AGED; COMPLICATION; CROSS INFECTION; DOSE RESPONSE; DRUG EFFECTS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SEPSIS; THIENAMYCINS;

EID: 84960490149     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.09.014     Document Type: Article

References (30)

1. Dautzenberg M.J., Wekesa A.N., Gniadkowski M., Antoniadou A., Giamarellou H., Petrikkos G.L., et al. The association between colonization with carbapenemase-producing Enterobacteriaceae and overall ICU mortality: an observational cohort study. Crit Care Med 2015, 43(6):1170-1177.
2. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of K. pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-796.
3. Ah Y.M., Kim A.J., Lee J.Y. Colistin resistance in K. pneumoniae. Int J Antimicrob Agents 2014, 44:8-15.
4. Capone A., Giannella M., Fortini D., Giordano A., Meledandri M., Ballardini M., et al. High rate of colistin-resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013, 19(1):E23-E30.
5. Qureshi Z.A., Paterson D.L., Potoski B.A., Kilayko M.C., Sandovsky G., Sordillo E., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56(4):2108-2113.
6. Tumbarello M., Viale P., Viscoli C., Trecarichi E.M., Tumietto F., Marchese A., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infec Dis 2012, 55(7):943-950.
7. Girometti N., Lewis R.E., Giannella M., Ambretti S., Bartoletti M., Tedeschi S., et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) 2014, 93(17):298-309.
8. Tascini C., Tagliaferri E., Giani T., Leonildi A., Flammini S., Casini B., et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing K. pneumoniae. Antimicrob Agents Chemother 2013, 57(8):3990-3993.
9. Satlin M.J., Kubin C.J., Blumenthal J.S., Cohen A.B., Furuya E.Y., Wilson S.J., et al. Comparative effectiveness of aminoglycosides, polymyxin B and tigecycline for clearance of carbapenem-resistant K. pneumoniae from urine. Antimicrob Agents Chemother 2011, 55(12):5893-5899.
10. Sbrana F., Malacarne P., Viaggi B., Costanzo S., Leonetti P., Leonildi A., et al. Carbapenem-sparing antibiotic regimens for infections caused by K. pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013, 56(5):697-700.
11. Daikos G.L., Tsaousi S., Tzouvelekis L.S., Anyfantis I., Psichogiou M., Argyropoulou A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014, 58(4):2322-2328.
12. Pereira J.C., Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Critical Care 2011, 15:R206.
13. Jaruratanasirikul S., Sriwiriyajan S., Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49(4):1337-1339.
14. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17:1135-1141.
15. Oliva A., D'Abramo A., D'Agostino C., Iannetta M., Mascellino M.T., Gallinelli C., et al. Synergistic activity and effectiveness of a double carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother 2014, 69(6):1718-1720.
16. Ceccarelli G., Falcone M., Giordano A., Mezzatesta M.L., Caio C., Stefani S., et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57(6):2900-2901.
17. Oliva A., Mascellino M.T., Cipolla A., D'Abramo A., De Rosa A., Savinelli S., et al. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis 2015, 33:132-134.
18. Karaiskos I, Masgala A, Galani L, Baziaka F, Giamarellou H. Double Carbapenem (DC) Regimens for Infections in Humans Due to Carbapenemase-Producing Klebsiella pneumoniae (CPKP). Poster K-186. 53rd ICAAC (10-13 September 2013).
19. Nogid B, Venugopalan V, Bias T, Rahman S, Nicolau D. Double carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae: from test tube to clinical practice. Poster 2110. 23rd ECCMID (27-30 April 2013).
20. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, Version 5.0, 2015 2013, http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf.
21. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41(2):580-637.
22. Giske C.G., Gezelius L., Samuelsen Ø., Warner M., Sundsfjord A., Woodford N. A sensitive and specific phenotypic assay for detection of metallo-beta-lactamases and KPC in K. pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect 2011, 17:552-556.
23. CLSI 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, seventh ed. Document M7-A7 CLSI, Wayne, PA.
24. Marques M.B., Brookings E.S., Moser S.A., Sonke P.B., Waites K.B. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997, 41(5):881-885.
25. Chen L.F., Anderson D.J., Paterson D.L. Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance. Infect Drug Resist 2012, 5:133-141.
26. Tumbarello M., Trecarichi E.M., De Rosa F.G., Giannella M., Giacobbe D.R., Bassetti M., et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015 Jul, 70(7):2133-2143.
27. Bulik C.C., Nicolau D.P. Double-carbapenem therapy for carbapenemase-producing K. pneumoniae. Antimicrob Agents Chemother 2011, 55(6):3002.
28. Giamarellou H., Galani L., Baziaka F., Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:2388-2390.
29. Garbati M.A., Al Godhair A.I. The growing resistance of Klebsiella pneumoniae; the need to expand our antibiogram: case report and review of the literature. Afr J Infect Dis 2013, 7(1):8-10.
30. Wiskirchena D.E., Crandonb J.L., Nicolau D.P. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2013, 41:582-585.